Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Sulphonamide resistance in E. coli remains high, despite prescribing restriction

A substantial decrease in prescribing sulphonamides in the UK over the past decade has failed to reduce resistance to this class of antibiotics, conclude authors of a study in this week's issue of the Lancet.

News image

fiogf49gjkf04

There is a clear link between heavy antimicrobial use and the emergence of resistant bacteria. Whether a reduction in antimicrobial use can reverse this process is less certain.

Lucinda Hall, and David Livermore, and colleagues from St Bartholomew's and The Royal London School of Medicine and Dentistry, and the Central Public Health Laboratory, England, investigated the effect of the 1995 national restriction of sulphonamide prescribing in the UK on the prevalence of sulphonamide resistance in Escherichia coli.

Over 350 clinical isolates of E. coli were collected in 1991 and 1999, and the presence and locations of sulphonamide-resistance genes were assessed.

Frequency of E. coli sulphonamide resistance:
1991: 40%
1999: 46%
Lancet

Despite a huge decrease in sulphonamide prescriptions - from 3,208,000 prescriptions in 1991 to 77,000 in 1999 - the frequency of resistance remained high (165/359 [46%] in 1999 compared with 143/360 [40%] in 1991).

The prevalence of one specific resistance gene (SUL II) increased from 27% in 1991 to 36.5% in 1999.

Lucinda Hall comments, "We would like to think that if we stop using an antibiotic so much, resistance will go away, and we'll be able to use it again.

"Our study shows that we can't depend on this happening - once resistance to an antibiotic is common, it is going to be very difficult to get rid of. In part, this is because the genes that cause resistance to disused drugs, like sulphonamides, are linked to those that cause resistance to antibiotics we continue to use."

David Livermore adds, "Nevertheless, using antibiotics more carefully should slow the development of new resistance; and this - coupled with the development of new drugs - is vital if we are to keep ahead of the bacteria".

In an accompanying Commentary, Burke Cunha from Winthrop-University Hospital, Mineola, New York, USA, comments that the antibiotic resistance observed in Hall and colleagues' study is unsurprising. This is because the sulphonamide-restriction programme did not restrict the use of other antibiotics with high resistance potential commonly used in general practice, such as tetracycline and ampicillin.

Lancet 2001; 357 (9265): 1307, 1325
27 April 2001

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us